Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Update

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the recipient of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 2,700 shares, a decline of 57.8% from the November 30th total of 6,400 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily volume of 20,000 shares, the days-to-cover ratio is presently 0.1 days.

Insider Activity

In other news, Director Aron R. English bought 10,101,010 shares of the stock in a transaction dated Monday, December 23rd. The stock was purchased at an average price of $0.99 per share, for a total transaction of $9,999,999.90. Following the acquisition, the director now owns 15,467,300 shares of the company’s stock, valued at $15,312,627. The trade was a 188.23 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 85.90% of the company’s stock.

Analysts Set New Price Targets

Separately, Benchmark reissued a “speculative buy” rating and issued a $8.00 price objective on shares of Anebulo Pharmaceuticals in a research note on Tuesday, November 19th.

Anebulo Pharmaceuticals Stock Up 4.9 %

ANEB opened at $1.70 on Friday. The business has a fifty day moving average of $1.57 and a 200 day moving average of $1.93. Anebulo Pharmaceuticals has a 52-week low of $0.80 and a 52-week high of $3.30. The stock has a market cap of $44.09 million, a P/E ratio of -5.67 and a beta of -1.09.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last posted its quarterly earnings results on Wednesday, September 25th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.08. Equities analysts anticipate that Anebulo Pharmaceuticals will post -0.52 EPS for the current fiscal year.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.